Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Learn more about:
Related Clinical Trial
A Safety Study of 212Pb-Pentixather Radioligand Therapy
Bronchoscopic Laser Ablation of Peripheral Lung Tumors
Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers
Personalized PRRT of Neuroendocrine Tumors
Clinical and Pathologic Studies in Neuroendocrine Tumors
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Active Surveillance in Early Lung Cancer
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Cabozantinib and Nivolumab for Carcinoid Tumors
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Endoscopic Treatment of Bronchial Carcinoid Tumors
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
A Study of Axitinib in Advanced Carcinoid Tumors
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors